Pantothenate kinase-associated neurodegeneration (Hallervorden–Spatz syndrome)

doi:10.1053/ejpn.2002.0606

European Journal of Paediatric Neurology

Volume 6, Issue 5, September 2002, Pages 243-247

https://doi.org/10.1053/ejpn.2002.0606 Get rights and content

Abstract

The arguments over the nomenclature of the syndrome are reviewed. Ethical considerations favour replacing the present eponyms with the title of panthothenate kinase-associated neurodegeneration (PKAN), now that more is known about the cause of the condition. The symptoms and signs of the syndrome are described, and these can present from infancy to adult life. Dystonia, involuntary movements and spasticity are prominent causes of disability. If the onset is delayed the presentation can be unusual. Tests that can help in diagnosis are reviewed, especially the ‘eye of the tiger’ revealed by magnetic resonance imaging scanning. Death usually occurs about 10 years after the onset, but the course may be more prolonged. The findings on autopsy are also considered, with the typical findings of iron pigment deposits and axonal spheroids. Then the causes are discussed. Once the responsible gene PANK2 had been discovered on chromosome 20 it was found that this encoded for pantothenate kinase which is essential for the synthesis of coenzyme A from pantothenate; and this is integral to fatty acid synthesis and energy metabolism. Also this can lead to a concentration of cysteine in the basal ganglia, and then to an accumulation of iron in these areas. The cysteine–iron complex will result in tissue damage by promoting oxidative stress, as in some other neurodegenerative diseases. The syndrome of PKAN can therefore be identified as a disorder of pantothanate, vitamin B5, metabolism. Infantile neuroaxonal dystrophy is briefly described as there have been suggestions that it is a variety of PKAN, but the evidence is in favour of the two diseases being separate entities. There may as yet be no specific treatment for this syndrome, but much can be done to help these children. Drugs may be needed to control epilepsy, and when dystonia is severe it may be possible to alleviate this by medical or surgical means. Also there will be other problems needing expert management, such as the provision of alternative means of communication if dysarthria is marked. The hope for the future is that now the cause has been found it will be possible to use methods such as antioxidative therapy and gene induction procedures.

References (0)

Cited by (56)

Diagnostic Imaging: Brain
2016, Diagnostic Imaging: Brain
Imaging in Neurology
2016, Imaging in Neurology
Mitochondrial protein associated neurodegeneration - Case report
2014, Neurologia i Neurochirurgia Polska
Neurodegeneration with brain iron accumulation (NBIA) is a group of genetic disorders with a progressive extrapyramidal syndrome and excessive iron deposition in the brain, particularly in the globus pallidus and substantia nigra. We present the case of a 31-year-old woman with mitochondrial protein associated neurodegeneration (MPAN). MPAN is a new identified subtype of NBIA, caused by mutations in C19orf12 gene. The typical features are speech and gait disturbances, dystonia, parkinsonism and pyramidal signs. Common are psychiatric symptoms such as impulsive or compulsive behavior, depression and emotional lability. In almost all cases, the optic atrophy has been noted and about 50% of cases have had a motor axonal neuropathy. In the MRI on T2- and T2*-weighted images, there are hypointense lesions in the globus palidus and substantia nigra corresponding to iron accumulation.
Mouse models of neurodevelopmental disease of the basal ganglia and associated circuits
2014, Current Topics in Developmental Biology
Citation Excerpt :
Damage to the striatum and associated structures (e.g., pallidum, thalamus) are a common cause of secondary dystonia (Marsden, Obeso, Zarranz, & Lang, 1985; Mehanna & Jankovic, 2013). Metabolic diseases that disrupt striatal function (e.g., Wilson's disease, pantothenate kinase-associated neurodegeneration) also cause secondary dystonia (Gordon, 2002; Lorincz, 2012). There are strong links between dopaminergic dysfunction and dystonia.
This chapter focuses on neurodevelopmental diseases that are tightly linked to abnormal function of the striatum and connected structures. We begin with an overview of three representative diseases in which striatal dysfunction plays a key role—Tourette syndrome and obsessive-compulsive disorder, Rett's syndrome, and primary dystonia. These diseases highlight distinct etiologies that disrupt striatal integrity and function during development, and showcase the varied clinical manifestations of striatal dysfunction. We then review striatal organization and function, including evidence for striatal roles in online motor control/action selection, reinforcement learning, habit formation, and action sequencing. A key barrier to progress has been the relative lack of animal models of these diseases, though recently there has been considerable progress. We review these efforts, including their relative merits providing insight into disease pathogenesis, disease symptomatology, and basal ganglia function.
Mitochondrial defects and oxidative stress in Alzheimer disease and Parkinson disease
2013, Free Radical Biology and Medicine
Citation Excerpt :
Moreover, a genetic interaction between LRRK2 and PINK1/parkin is identified in Drosophila [195,196], and PINK1 deficiency-induced mitochondrial morphological abnormalities can be prevented by lrk-1 (Caenorhabditis elegans LRRK2 homolog) deficiency [197]. That LRRK2 may influence mitochondrial dynamics was first implicated in primary human fibroblasts derived from PD patients carrying the LRRK2 G2019S mutant in which increased mitochondrial elongation and interconnectivity along with mitochondrial dysfunction were identified [198]. Most recent studies demonstrated that overexpression of wild-type LRRK2 causes mitochondrial fragmentation and ultrastructural damage along with mitochondrial dysfunction including increased ROS, which is further exacerbated by expression of PD-associated mutants (R1441C or G2019S) in both SH-SY5Y and differentiated primary cortical neurons [199].
Alzheimer disease (AD) and Parkinson disease (PD) are the two most common age-related neurodegenerative diseases characterized by prominent neurodegeneration in selective neural systems. Although a small fraction of AD and PD cases exhibit evidence of heritability, among which many genes have been identified, the majority are sporadic without known causes. Molecular mechanisms underlying neurodegeneration and pathogenesis of these diseases remain elusive. Convincing evidence demonstrates oxidative stress as a prominent feature in AD and PD and links oxidative stress to the development of neuronal death and neural dysfunction, which suggests a key pathogenic role for oxidative stress in both AD and PD. Notably, mitochondrial dysfunction is also a prominent feature in these diseases, which is likely to be of critical importance in the genesis and amplification of reactive oxygen species and the pathophysiology of these diseases. In this review, we focus on changes in mitochondrial DNA and mitochondrial dynamics, two aspects critical to the maintenance of mitochondrial homeostasis and function, in relationship with oxidative stress in the pathogenesis of AD and PD.
Transcranial ultrasound in adults and children with movement disorders
2012, Perspectives in Medicine
Since the first discovery, that ultrasound can overcome the skull allowing examination of the intracranial blood-flow as well as the first description of substantia nigra (SN) signal alterations via B-mode sonography, a plethora of applications especially in the field of movement disorders have been fostered. Up to now, however, most studies investigated adult individuals, even though numerous of the diseases studied have their onset already during childhood or adolescence. This overview summarizes recent studies of transcranial B-mode sonography (TCS) within the movement disorder field and outlines potential implications for pediatric applications.

View all citing articles on Scopus

^f1: Correspondence: Dr Neil Gordon, Huntlywood, 3 Styal Road, Wilmslow, SK9 4AE, UK; Tel: 01625 525437;e-mail:[email protected]

View full text

What's new in?Pantothenate kinase-associated neurodegeneration (Hallervorden–Spatz syndrome)

Abstract

What's new in?
Pantothenate kinase-associated neurodegeneration (Hallervorden–Spatz syndrome)